Novo Nordisk files suit against Mylan to block entry of generic Victoza drug in US

“We can confirm that Novo Nordisk has filed a lawsuit against Mylan for patent infringement of Victoza,” the company said in an e-mail.

COPENHAGEN: Novo Nordisk (NOVOb.CO) said on Thursday it has filed litigation in a Delaware district court against Mylan (MYL.O) aimed at blocking its attempt to market a generic version of the Danish insulin maker’s drug Victoza.

“We can confirm that Novo Nordisk has filed a lawsuit against Mylan for patent infringement of Victoza,” the company said in an e-mail.

Victoza is a medication used to treat diabetes mellitus type 2 and obesity. In diabetes, it is a less preferred agent. Its effects on long term health outcomes like heart disease and life expectancy are unclear.

Read Also: Novo Nordisk buys drug factory in North Carolina for assistance in manufacturing, packaging new diabetes drug

Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Read Also: Novo Nordisk gets USFDA for use of Victoza to treat type 2 diabetes in pediatric patients